PACB Stock Cash Flow Statements

Pacific Biosciences of California Quarterly Cash Flow Statements Chart

Quarterly

Annual

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

Pacific Biosciences of California Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31

cash flows from operating activities
net income	-41,930,000	-426,075,000	2,371,000	-60,725,000	-173,319,000	-78,178,000	-82,018,000	-66,869,000	-69,833,000	-88,015,000	-84,384,000	-76,971,000	-71,394,000	-81,499,000	-69,329,000	16,542,000	-41,001,000	-87,435,000	74,935,000	-23,708,000	-23,086,000	1,262,000	-91,000	-29,123,000	-24,596,000	-30,324,000	-30,799,000
adjustments to reconcile net income to net cash from operating activities
depreciation	2,659,000	5,131,000	2,842,000	4,193,000	3,499,000	3,240,000	2,976,000	2,903,000	2,829,000	2,755,000	2,543,000	2,346,000	2,323,000	2,268,000	2,256,000	1,745,000	1,592,000	1,606,000	1,601,000	1,581,000	1,589,000	1,657,000	1,782,000	1,897,000	1,790,000	1,796,000
amortization of intangible assets	1,019,000	366,390,000				6,853,000	6,853,000	942,000	232,000	234,000		229,000	228,000	228,000
amortization of right-of-use assets	904,000	1,258,000	1,253,000	5,054,000	3,937,000	1,921,000	1,870,000	1,610,000	1,803,000	1,527,000	1,773,000	1,740,000	1,716,000	1,696,000
share-based compensation expense	11,895,000	9,201,000	16,033,000	18,259,000	17,219,000	19,525,000		19,691,000	17,891,000	17,952,000
impairment charges	0	15,000,000
accretion of discount and amortization of premium on marketable securities	-1,276,000	-1,706,000	-2,381,000	-3,091,000	-3,541,000	-4,031,000		-3,975,000	-3,958,000	-2,155,000
change in the estimated fair value of contingent consideration	0	-18,700,000	-1,950,000	1,170,000	0	-70,000	1,100,000	-271,000	1,975,000	12,256,000	4,598,000	4,280,000	-5,438,000	-1,063,000
inventory provision	883,000	7,659,000	903,000	-207,000	3,919,000	3,000	5,893,000	396,000	774,000	3,521,000
deferred income taxes	0	-546,000					-718,000								1,175,000
other	340,000	719,000	-1,630,000	300,000	299,000	403,000	392,000								1,000
changes in assets and liabilities
accounts receivable	-612,000	-4,121,000	1,859,000	3,050,000	-2,110,000	6,292,000	-6,129,000	-6,452,000	5,555,000	-10,803,000	3,970,000	4,302,000	794,000	-3,611,000	-295,000	-3,772,000	-7,030,000	3,931,000	-5,031,000	-460,000	-4,021,000	7,909,000	-5,300,000	2,157,000	-4,844,000	1,316,000	-2,191,000
inventory	-1,330,000	-2,538,000	7,074,000	1,373,000	-5,112,000	-11,655,000	9,008,000	-3,146,000	-6,384,000	-13,319,000	-13,206,000	-7,534,000	-6,891,000	-6,275,000	-6,978,000	-423,000	-2,474,000	-2,556,000	1,892,000	834,000	-448,000	-3,374,000	1,660,000	2,295,000	1,848,000	-1,888,000	609,000
prepaid expenses and other assets	3,383,000	3,426,000	-1,306,000	-25,000	508,000	3,051,000	-1,697,000	-1,202,000	803,000	-6,888,000	-6,639,000	-5,345,000	845,000	-1,185,000	-1,023,000	306,000	368,000	-675,000	-1,279,000	-308,000	582,000	-58,000	-761,000	-150,000	301,000	87,000	-827,000
accounts payable	1,020,000	-1,525,000	3,627,000	-5,612,000	-3,254,000	6,644,000	-1,500,000	-2,556,000	-806,000	5,068,000	-486,000	180,000	-5,042,000	6,373,000	6,167,000	-1,207,000	1,250,000	153,000	-2,117,000	-1,916,000	3,090,000	-4,129,000	259,000	769,000	-1,390,000	2,075,000	687,000
accrued expenses	-2,718,000	311,000	323,000	-3,415,000	503,000	-23,753,000	11,048,000	8,011,000	7,230,000	-13,186,000	7,403,000	303,000	5,877,000	-17,234,000	5,053,000	4,707,000	8,240,000	-2,680,000	2,456,000	2,685,000	-5,760,000	4,721,000	-2,581,000	1,716,000	2,987,000	-1,703,000	3,702,000
deferred revenue	-524,000	1,332,000	-2,983,000	-2,171,000	1,445,000	1,601,000	-5,553,000	-2,550,000	-2,740,000	423,000	-159,000	-1,460,000	-4,064,000	1,949,000	7,806,000	8,528,000	4,398,000	5,004,000	1,547,000	280,000	-128,000	-970,000
operating lease liabilities	-112,000	-1,618,000	-2,668,000	-4,504,000	-2,372,000	-2,376,000	-2,363,000	-2,282,000	-2,145,000	-1,969,000	-1,819,000	-2,072,000	-1,949,000	-1,884,000	-1,759,000	-1,087,000	-1,078,000	-1,066,000	-1,011,000	-956,000	-904,000	-931,000	-891,000
other liabilities	-2,978,000	2,346,000	2,441,000	-5,964,000	4,063,000	-5,152,000	3,596,000	-1,686,000	2,994,000	-2,455,000	2,587,000	-2,079,000	2,891,000	-2,512,000	2,193,000	-2,064,000	2,048,000	-2,980,000	4,686,000	-1,603,000	1,474,000	489,000	-885,000	1,023,000	622,000	-1,323,000	-41,000
net cash from operating activities	-29,377,000	-44,056,000	-30,650,000	-45,463,000	-54,263,000	-75,682,000	-57,560,000	-65,181,000	-41,741,000	-94,691,000	-60,566,000	-63,053,000	-60,563,000	-79,029,000	-31,708,000	-40,656,000	-15,712,000	-23,104,000	-14,263,000	-17,808,000	-23,789,000	75,363,000	-18,180,000	-17,260,000	-17,559,000	-25,313,000	-18,985,000
capex	-550,000	-1,389,000	-1,617,000	787,000	-1,479,000	-3,879,000	-2,024,000	-830,000	-2,268,000	-3,721,000	-4,904,000	-4,189,000	-4,019,000	-3,638,000	-2,842,000	-1,119,000	-1,569,000	-401,000	-67,000	-536,000	-319,000	-117,000	-141,000	-829,000	-613,000	-1,253,000	-58,000
free cash flows	-29,927,000	-45,445,000	-32,267,000	-44,676,000	-55,742,000	-79,561,000	-59,584,000	-66,011,000	-44,009,000	-98,412,000	-65,470,000	-67,242,000	-64,582,000	-82,667,000	-34,550,000	-41,775,000	-17,281,000	-23,505,000	-14,330,000	-18,344,000	-24,108,000	75,246,000	-18,321,000	-18,089,000	-18,172,000	-26,566,000	-19,043,000
cash flows from investing activities
purchases of property and equipment	-550,000	-1,389,000
purchases of intangible assets	0	-5,000,000
purchases of investments	-56,172,000	-61,820,000		-114,600,000	-111,657,000	-191,907,000		-76,869,000
maturities of investments	82,005,000	113,443,000	113,531,000	128,817,000	189,973,000	161,650,000	138,268,000	320,124,000	147,265,000	163,864,000	220,375,000	124,910,000	108,455,000	122,060,000	199,220,000	73,110,000	81,775,000	68,400,000	38,900,000	52,250,000	43,700,000	18,750,000	11,750,000	24,950,000	27,550,000	56,860,000	12,500,000
net cash from investing activities	25,283,000	45,234,000	58,238,000	23,065,000	76,837,000	-34,136,000		242,323,000	-98,591,000	-72,553,000		53,908,000	-60,281,000	42,053,000		-291,646,000	-460,808,000	8,170,000		-63,641,000	-2,859,000	-54,327,000		19,659,000	7,812,000	37,984,000	-5,513,000
cash flows from financing activities
proceeds from issuance of common stock from equity plans	0	1,959,000	0	812,000	0	6,891,000	936,000	4,562,000	2,586,000	7,235,000	1,247,000	3,543,000	848,000	5,592,000	1,685,000	4,810,000	2,968,000	22,343,000	32,186,000	13,347,000	628,000	199,000	131,000	327,000	1,400,000	6,690,000	5,471,000
notes payable principal payoff				0	-152,000	-338,000	-445,000	-486,000	-465,000	-446,000	-428,000	-410,000	-393,000	-377,000					0	0	0	-16,000,000
net cash from financing activities	0	1,959,000		812,000	-152,000	6,553,000	-81,602,000	-781,000	-4,715,000	195,989,000	819,000	3,133,000	455,000	5,215,000	1,324,000	299,656,000	2,880,000	865,721,000	125,877,000	107,135,000	628,000	18,199,000	18,131,000	327,000	1,400,000	6,690,000	5,279,000
net decrease in cash, cash equivalents, and restricted cash
cash, cash equivalents, and restricted cash at beginning of period	0	57,592,000		0	0	182,633,000	0	0	0	328,311,000	0
cash, cash equivalents, and restricted cash at end of period	-4,094,000	60,729,000		-21,586,000	22,422,000	79,368,000	-205,737,000	176,361,000	-145,047,000	357,056,000	20,656,000
cash and cash equivalents at end of period	-3,704,000	58,507,000		-21,544,000	22,880,000	76,646,000	-205,737,000	176,361,000	-144,547,000	353,834,000	20,656,000	-6,012,000	-118,129,000	428,574,000	35,337,000	-34,406,000	-472,604,000	932,398,000	12,583,000	25,686,000	-25,520,000	68,862,000	-3,457,000	2,726,000	-7,847,000	38,205,000	-19,219,000
restricted cash at end of period	-390,000	2,222,000		-42,000	-458,000	2,722,000	0	0	-500,000	3,222,000	0	0	-2,260,000	5,482,000	32,000	1,760,000	-1,036,000	4,336,000	836,000	0	-500,000	4,000,000	0	0	-500,000	4,500,000	0
supplemental disclosure of non-cash investing and financing activities
right-of-use asset and lease liability recognized due to lease extension	0	29,575,000
net increase in cash, cash equivalents, and restricted cash		3,137,000				-103,265,000	-205,737,000			28,745,000	20,656,000
merger-related compensation expense							0
loss on extinguishment of debt							0	0
gain on debt restructuring
contingent consideration liability							-14,150,000
purchase of property and equipment			-1,617,000	787,000	-1,479,000	-3,879,000	-2,024,000	-830,000	-2,268,000	-3,721,000	-4,904,000	-4,189,000	-4,019,000	-3,638,000	-2,842,000	-1,119,000	-1,569,000	-401,000	-67,000	-536,000	-319,000	-117,000	-141,000	-829,000	-613,000	-1,253,000	-58,000
purchase of intangible assets
cash paid for purchases of acquired entities, net of cash acquired
purchase of investments										-233,291,000	-134,889,000	-66,813,000	-164,717,000	-76,369,000	-130,625,000	-222,021,000	-570,974,000	-64,426,000	-138,728,000	-115,355,000	-46,240,000	-72,960,000	-15,017,000	-5,962,000	-19,125,000	-17,623,000	-17,955,000
sales of investments			26,795,000				0	0	0	595,000					0	178,177,000	29,960,000	4,597,000					0				0
proceeds from issuance of common stock under equity offerings, net of issuance costs							0	0	0	189,200,000					-1,000
payment of debt issuance costs							-50,000	-489,000
payment of contingent consideration							-82,043,000
amortization of acquired intangible assets				6,852,000
goodwill impairment				0
cash paid for purchase of apton, net of cash acquired
gain from continuation advances															0	0	0	52,000,000		0	0	-34,000,000
share-based compensation
amortization of premium and accretion of discount on marketable securities											-1,313,000
net cash from in investing activities
continuation advances															0	0	0	-52,000,000		0
proceeds from issuance of convertible senior notes, net of issuance costs															0	0	-88,000	895,624,000
supplemental disclosure of cash flow information
interest paid
inventory transferred to property and equipment																			556,000	175,000			278,000	357,000			1,207,000
property and equipment transferred to inventory
right-of-use asset and liability additions and modifications
issuance of common stock in acquisition of apton and omniome
issuance of common stock in connection with apton liquidity event bonus plan
convertible senior notes exchange
issuance of common stock following milestone achievement
amortization of debt discount and financing costs									162,000	162,000	160,000	161,000	160,000	159,000	158,000	155,000	152,000	74,000	0	0	0	129,000	325,000	313,000	295,000	279,000	275,000
loss on disposition of equipment									-156,000	201,000	196,000	5,000	-23,000	100,000
amortization of intangibles
cash paid for purchase of circulomics, net of cash acquired															0
cash paid for purchase of omniome, net of cash acquired															0
issuance of common stock in acquisition of omniome															1,000
income from continuation advances
stock-based compensation												18,936,000	19,019,000	22,703,000	18,938,000	28,447,000	15,805,000	10,165,000	5,275,000	4,992,000	3,234,000	4,032,000	3,869,000	4,062,000	4,089,000	4,381,000	7,522,000
amortization from investment premium													385,000	758,000
net increase in cash and cash equivalents and restricted cash													-120,389,000	-31,761,000	35,369,000	-32,646,000	-473,640,000	850,787,000	13,119,000	25,686,000	-26,020,000	39,235,000	-3,457,000	2,726,000	-8,347,000	19,361,000
cash and cash equivalents and restricted cash at beginning of period													0	465,817,000	0	0	0	85,947,000	300,000	0	0	33,627,000	0	0	0	23,344,000	0
cash and cash equivalents and restricted cash at end of period													-120,389,000	434,056,000	35,369,000	-32,646,000	-473,640,000	936,734,000	13,419,000	25,686,000	-26,020,000	72,862,000	-3,457,000	2,726,000	-8,347,000	42,705,000	-19,219,000
income from derivative
amortization															904,000	1,325,000	1,217,000	565,000		36,000	-94,000	-83,000				-416,000
amortization of operating lease right-of-use assets																812,000	801,000	790,000		735,000	683,000	709,000		665,000	636,000	653,000
deferred gain from reverse termination fee																				0	0	98,000,000
issuance costs paid for underwritten public equity offering																	0	-246,000
gain from continuation advances from illumina
(gain) income from derivative
amortization and accretion for investment premium
continuation advances from illumina
proceeds from issuance of common stock from underwritten public equity offerings, net of issuance costs
gain on derivative																									0	-16,000
proceeds from issuance of common stock from underwritten public equity offering, net of issuance costs
supplemental disclosure of non-cash operating activities
inventory transferred from property and equipment																								2,194,000
proceeds from continuation advances																						34,000,000
loss on return of building under capital lease
proceeds from disposal of property and equipment
proceeds from issuance of common stock from "at-the-market" offerings, net of issuance costs
property and equipment paid for by landlord
changes in deposits for property and equipment paid in prior period
property and equipment returned to landlord
(gain) loss on derivative
accretion from investment discount																								-144,000
(gain) loss on disposition of equipment
deferred service revenue																								-347,000	964,000	-230,000	671,000
depreciation and amortization
non-cash portion of gain on lease amendments
deferred contractual revenue
net decrease in cash and cash equivalents and restricted cash
property and equipment paid by landlord
other items
disposal of property and equipment
notes payable principal payment
proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs
changes in unpaid property and equipment
notes payable principal paying off
impact from adoption of asc 606 revenue from contracts with customers
inventory transferred to (from) property and equipment
long-term restricted cash
proceeds from issuance of common stock from "at-the-market" offering, net of issuance costs
net decrease in cash and cash equivalents
cash and cash equivalents at beginning of period
net increase in cash and cash equivalents
proceeds from issuance of common stock from underwritten public equity offering, net of issue costs
purchase of property and equipment through accounts payable
instruments that were transferred from inventory to property and equipment
proceeds from issuance of debt agreement, net of issuance costs
leased instruments that were transferred from inventory to property and equipment
inventory transferred to (from) property and equipment for internal use
proceeds from issuance of facility agreement, net of issuance costs
accrued expenses and other current liabilities
deferred rent and other long-term liabilities
other long-term liabilities
proceeds from issuance of common stock, net of issuance costs
proceeds from issuance of debt facility, net of issuance costs
lease incentives and other long-term liabilities
proceeds from issuance of convertible preferred stock
proceeds from issuance of common stock
assets acquired under facility lease
additions to property and equipment under tenant improvement allowances
inventory transferred to property and equipment for internal use
conversion of convertible preferred stock to common stock upon ipo
reclassification of preferred warrants to common stock warrants
issuance of common stock related to convertible preferred stock offering
vesting of stock options related to early exercises
purchases of property and equipment through accrued liabilities
proceeds from exercise of junior preferred stock options
proceeds from issuance of common stock in ipo, net of issuance costs
repurchases of common stock
payment of notes payable
assets acquired under facility financing obligation
prepaid expenses and other current assets
other long-term assets
sales and maturities of investments
proceeds from exercise of common stock options
repurchases of junior preferred stock
issuance of convertible preferred stock warrants
reclassification of convertible preferred stock warrants to liabilities
amortization of deferred financing costs
change in convertible preferred stock warrant liability fair value
proceeds from issuance of notes payable

We provide you with 20 years of cash flow statements for Pacific Biosciences of California stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Pacific Biosciences of California stock. Explore the full financial landscape of Pacific Biosciences of California stock with our expertly curated income statements.

The information provided in this report about Pacific Biosciences of California stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.